Atossa Therapeutics Updates on Promising (Z)-Endoxifen Research at MDA Conference

Atossa Therapeutics, Inc. recently delivered a significant clinical trial update regarding (Z)-endoxifen at the MDA Clinical & Scientific Conference held on March 11, 2026, in Orlando, Florida. This groundbreaking research focused on the preclinical findings related to Duchenne muscular dystrophy (DMD), a debilitating condition marked by progressive muscle degeneration.

Key Findings from the Research

The study utilized the mdx5Cv dystrophic mouse model, widely recognized for its reliability in DMD preclinical research. Findings indicate that (Z)-endoxifen markedly improved both muscle strength and motor performance in affected juvenile and adult mice. This was particularly notable as the treatment also demonstrated enhanced resilience to muscle injuries induced by contraction.

Moreover, the treatment resulted in favorable alterations in body composition, showing an increase in lean mass juxtaposed with a reduction in fat mass. Not only were biochemical and histological markers of muscle damage significantly decreased, but the overall therapy was well tolerated without any adverse findings noted.

Clinical Implications of the Findings

DMD is a progressive neuromuscular disorder that poses severe challenges for affected individuals, leading to symptoms like chronic muscle degeneration, inflammation, and fibrosis. Although existing therapies have enhanced disease management to some extent, a significant gap persists for more effective treatments.

The evidence gathered from this preclinical research suggests that (Z)-endoxifen could address various facets of DMD pathology, including mitigating muscle weakness, structural damage, and the decline of functional abilities. According to Dr. Steven C. Quay, Chairman and CEO of Atossa Therapeutics, these promising results advocate for continued clinical exploration of (Z)-endoxifen as a possible new treatment avenue for DMD patients.

Understanding Duchenne Muscular Dystrophy

Duchenne muscular dystrophy is a rare, progressive disorder caused by mutations in the dystrophin gene, often presenting symptoms early in childhood. These symptoms encompass gradual muscle weakening, loss of the ability to walk, breathing difficulties, and cardiomyopathy, with a typically fatal prognosis. Despite advancements in treatment, the quest for safe, effective, and accessible therapeutic options remains a pressing concern.

About (Z)-Endoxifen

(Z)-endoxifen stands out as a potent Selective Estrogen Receptor Modulator/Degrader (SERM/D), exhibiting unique activity across various biological mechanisms that pique interest in oncology and rare diseases. Atossa's proprietary oral formulation has established a favorable safety profile distinct from tamoxifen, making it a candidate worthy of further evaluation. The ongoing research is supported by a robust global intellectual property portfolio, including several recently issued U.S. patents and numerous pending applications worldwide.

Atossa Therapeutics: Leading the Charge

Atossa Therapeutics, Inc., traded on Nasdaq under ATOS, is committed to developing innovative therapies in oncology and other areas where significant medical needs exist. Their leading candidate, (Z)-endoxifen, is currently being explored across several clinical settings. The company's focused approach emphasizes disciplined capital allocation towards programs poised for future regulatory submissions, along with potential commercialization. To learn more about Atossa's endeavors and regulatory filings, interested readers can visit Atossa Therapeutics' website.

Conclusion

The findings presented at the MDA conference mark a critical step forward in understanding and potentially treating DMD. As the clinical development of (Z)-endoxifen continues, the implications for improving muscle performance and reducing damage biomarkers offer hope for a condition that has long challenged patients and healthcare providers alike. The landscape of DMD treatment may very well shift as researchers, clinicians, and companies like Atossa work towards unveiling new therapeutic possibilities.